EOFlow, the wearable insulin pump EOPatch developer, has been embroiled in an intellectual property right (IPR) infringement lawsuit in the U.S.

In a public filing Wednesday, EOFlow said that INSULET, a U.S. developer of wearable insulin pumps, has filed an IPR infringement and unfair competition lawsuit against the Korean company.

The court of jurisdiction is the U.S. District Court for the District of Massachusetts, and the trial number is Case No. 1:23-cv-11780.

The amount of the claim has not been fixed yet. EOFlow said it would file a corrective notice when the amount is finalized.

Earlier, INSULET also filed a patent infringement lawsuit in Germany against EOFlow's European partner, Menarini, and requested a preliminary injunction against selling its insulin pump product, GlucoMen Day PUMP, known as EOPatch in Korea.

INSULET, which succeeded in developing a wearable insulin pump for the first time worldwide, is competing with EOFlow, which developed the world's second wearable insulin pump.

"We will appoint a litigation representative and actively respond to the legal proceedings," the Korean company said.

EOFlow's stock price closed at 24,950 won ($18.9) Wednesday, down 10.73 percent or 3,000 won, from the previous day's close.

Medtronic, a global medical equipment maker, is scheduled to acquire EOFlow later in the year. EOFlow CEO Kim Jae-jin, its largest shareholder, signed a share transfer agreement with Medtronic Korea Holdings, a company established by Medtronic in May, which entails a change in the largest shareholder.

Accordingly, Kim will transfer about 5.64 million shares (18.54 percent of the company’s total outstanding shares) to Medtronic Korea at 30,000 won per share. The total price is about 169.2 billion won.

Besides, Medtronic plans to acquire 22,955,839 shares, representing more than 50 percent of EOFlow’s total shares, by acquring12.92 million shares by participating in the third party-allotment capital increase of EOFlow in October and making a tender offer for existing stocks at 30,000 won per share, and push ahead with voluntary delisting of EOFlow.

Medtronic said its total purchase price of EOFlow is about $738 million (971 billion won). Medtronic holds more than half of the global market for regular insulin pumps and will add wearable insulin pump technology to its portfolio with the acquisition of EOFlow, it added.